Keros Therapeutics (NASDAQ: KROS) furnishes updated corporate investor presentation

Rhea-AI Filing Summary

Keros Therapeutics, Inc. furnished an updated corporate presentation for use in meetings with investors, analysts and others. The company made this updated presentation available on its website and also attached it as Exhibit 99.1 to this current report. The presentation is dated January 2026 and is meant to provide additional background on the business.

The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and is not considered filed for purposes of certain liability provisions of the Securities Exchange Act. It will only be incorporated into other securities filings if specifically referenced there.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001664710FALSE00016647102026-01-092026-01-090001664710us-gaap:CommonStockMember2026-01-092026-01-090001664710us-gaap:PreferredStockMember2026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Keros Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39264

81-1173868

(state or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

1050 Waltham Street, Suite 302 Lexington, Massachusetts

02421

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 314-6297

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

KROS

The Nasdaq Stock Market LLC

Preferred Share Purchase Rights

N/A

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01    Regulation FD Disclosure.

On January 9, 2026, Keros Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company’s website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.						Description
99.1						Corporate Presentation dated January 2026.
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KEROS THERAPEUTICS, INC.
By:						/s/ Jasbir Seehra
						Jasbir Seehra, Ph.D. Chief Executive Officer

Dated: January 9, 2026

FAQ

What did Keros Therapeutics (KROS) report in this 8-K filing?

Keros Therapeutics reported that it updated its corporate presentation for use in meetings with investors, analysts and others, and furnished it as Exhibit 99.1.

Where can investors find the new Keros Therapeutics corporate presentation?

The updated corporate presentation is available through Keros Therapeutics' website and is also attached to the filing as Exhibit 99.1 dated January 2026.

Is the Keros Therapeutics investor presentation considered filed with the SEC?

No. The company states that the information in this report and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act.

Which SEC item does this Keros Therapeutics 8-K relate to?

The report is made under Item 7.01 Regulation FD Disclosure, covering the furnishing of the updated corporate presentation to ensure fair disclosure to the market.

What exhibits are included with this Keros Therapeutics (KROS) 8-K?

The filing includes Exhibit 99.1 (Corporate Presentation dated January 2026) and Exhibit 104 (Cover Page Interactive Data File embedded in the Inline XBRL document).

Who signed the Keros Therapeutics 8-K furnishing the updated presentation?

The report was signed on behalf of Keros Therapeutics, Inc. by Jasbir Seehra, Ph.D., Chief Executive Officer.